The Synergism between Belotecan and Cisplatin in Gastric Cancer.
- Author:
Joo Young JUNG
1
;
Sang Hyun SONG
;
Tae Young KIM
;
Jung Hyun PARK
;
Hyun Soon JONG
;
Seock Ah IM
;
Tae You KIM
;
Yung Jue BANG
;
Noe Kyoung KIM
Author Information
1. Department of Internal Medicine, Hangang Sacred Heart Hospital, Hallym University College of Medicine, Korea.
- Publication Type:In Vitro ; Original Article
- Keywords:
Belotecan;
Cisplatin;
Synergism;
Stomach neoplasms
- MeSH:
Cell Line;
Cisplatin*;
DNA;
DNA Adducts;
Stomach Neoplasms*
- From:Cancer Research and Treatment
2006;38(3):159-167
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We wanted to demonstrate the anti-cancer effect and interaction between belotecan and cisplatin on gastric cancer cell line and we evaluated the mechanisms of this synergistic effect in vitro. MATERIALS AND METHODS: The growth inhibitory effect of belotocan and cisplatin against several gastric cancer cell lines (SNU-5, SNU-16 and SNU-601) was estimated by tetrazolium dye assay. The effect of a combination treatment was evaluated by the isobologram method. The biochemical mechanisms for the interaction between the drugs were analyzed by measuring the formation of DNA interstrand cross-links (ICLs) and DNA topo-I activity. RESULTS: Belotecan showed synergism with cisplatin for growth inhibitory effect on the gastric cancer cell lines SNU-5, and SNU-16, but this was subadditive on the SNU-601 cell line. The formation of DNA ICLs in SNU-16 cells by cisplatin was increased by combination with belotecan, but this was not affected in SNU-601 cells. The topo-I inhibition by belotecan was enhanced at high concentrations of cisplatin in SNU-16, but not in SNU-601 cells. CONCLUSION: Belotecan and cisplatin show various combination effect against gastric cancer cells. The synergism between cisplatin and belotecan could be the result of one of the following mechanisms: the modulating effect of belotecan on the repair of cisplatin-induced DNA adducts and the enhancing effect of cisplatin on the belotecan-induced topo-I inhibitory effect.
